Aragen Life Sciences
Aragen Life Sciences, a prominent player in the biotechnology sector, is headquartered in India and operates extensively across major regions, including North America and Europe. Founded in 2000, the company has established itself as a leader in providing integrated solutions for drug discovery, development, and manufacturing. Aragen's core offerings encompass a wide range of services, including biologics, small molecules, and custom research, distinguished by their commitment to innovation and quality. The company has achieved significant milestones, such as expanding its capabilities in biologics and securing partnerships with leading pharmaceutical firms. With a strong market position, Aragen Life Sciences is recognised for its expertise and reliability, making it a preferred partner for clients seeking comprehensive life science solutions.
DitchCarbon Score
How does Aragen Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aragen Life Sciences's score of 71 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aragen Life Sciences's reported carbon emissions
In 2023, Aragen Life Sciences reported total greenhouse gas emissions of approximately 54,000,000 kg CO2e, comprising 9,544,000 kg CO2e from Scope 1, 37,600,000 kg CO2e from Scope 2, and 55,072,000 kg CO2e from Scope 3 emissions. This marked a significant reduction in Scope 1 emissions compared to previous years, where emissions were 13,252,000 kg CO2e in 2022 and 12,231,000 kg CO2e in 2021. Aragen Life Sciences has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by FY2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 50.4% and Scope 3 emissions by the same percentage by FY2033, using FY2023 as the baseline year. Long-term goals include a 90% reduction in absolute emissions across all scopes by FY2050. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. The commitment includes addressing land-related emissions and removals from bioenergy feedstocks, demonstrating Aragen's proactive approach to climate action within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 10,268,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 25,554,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aragen Life Sciences is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
